ClinicalTrials.gg
CompletedNCT00747123Updated Oct 3, 2024Results posted

A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma

A Phase 2 interventional study of ACE-011 and Placebo in Multiple Myeloma, sponsored by Celgene. Completed at 2 sites in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-03.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 149 studies in Multiple Myeloma by Bristol-Myers Squibb — 9 open to participants now, 18 under way, 6 of them phase 3. Multiple Myeloma · Bristol-Myers Squibb.

Enrollment
84th of 108
30 · median 83
Started
2008
with 9 others
Phase 2
24 of 149
1 open now
Registered
25th of 149
by date

Among the 149 studies in Multiple Myeloma by Bristol-Myers Squibb, this one is the 84th largest by enrollment of the 108 interventional ones that give a count, is one of 10 that started in 2008, is one of 24 in phase 2, and was the 25th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

9 of the 149 studies in Multiple Myeloma by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Multiple Myeloma by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

Multi-center, randomized, multiple-dose study to evaluate the safety, tolerability and efficacy of ACE-011 in patients with osteolytic lesions of multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patient at least 18 years of age with stage II or III multiple myeloma
  • One or more lytic bone lesions
  • If currently receiving bisphosphonate therapy, have been on a stable dose for ≥ 2 months before dosing day 1 or must not have received bisphosphonates within 2 months of dosing day 1
  • If patient has undergone previous autologous or allogenic hematopoietic stem cell transplantation (), they must be stable (in the opinion of the investigator) and be a minimum of 6 months since HSCT
  • Has planned HSCT for the duration of the study
  • Has moles or lesions that are currently undiagnosed, but are suspect for
  • Has an underlying condition that may result in abnormal bone metabolism other than cancer related bone lesions, such as a history of hyperparathyroidism, hypoparathyroidism, hypocalcemia, rheumatoid arthritis, myeloproliferative disorder, gout, Paget's disease of the bone, or osteomalacia; patients with a diagnosis of osteoporosis prior to multiple myeloma diagnosis are eligible to participate.

Key Exclusion Criteria:

  • Known underlying condition that may result in abnormal bone metabolism other than cancer related bone lesions
  • History of polyneuropathy ≥ grade 3
  • Patients with plasma cell leukemia
  • Planned stem cell transplant (HSCT) or radiation for the duration of the study
  • Skeletal related event within 2 weeks of study enrollment
  • Has received erythropoiesis-stimulating agents (ESAs) within the last 21 days or is planned to receive ESAs during the course of the study
  • Has received anti-myeloma therapy within the last 21 days
  • Is scheduled to receive local radiation to bone during the course of the study
  • Has taken estrogen, androgen, anabolic steroids, calcitonin or other bone-active drugs within 4 months of study enrollment
  • Woman of (not undergone a hysterectomy or who have not been for at least 24 consecutive months)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Subcutaneous injection on days 1, 29, 57 and 85.

    Biological: Placebo

  • Experimental
    ACE-011 0.1 mg/kg

    Subcutaneous injection of ACE-011 0.1 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).

    Biological: ACE-011

  • Experimental
    ACE-011 0.3 mg/kg

    Subcutaneous injection of ACE-011 0.3 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).

    Biological: ACE-011

  • Experimental
    ACE-011 0.5 mg/kg

    Subcutaneous injection of ACE-011 0.5 mg/kg every 28 days totaling four doses (days 1, 29, 57 and 85).

    Biological: ACE-011

Interventions

  • BiologicalACE-011

    ACE-011 given by the subcutaneous route of administration monthly for 4 doses.

    Also known as: hActRIIA-IgG1

  • BiologicalPlacebo

    Placebo given by the subcutaneous route of administration monthly for 4 doses.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    A treatment emergent adverse event (TEAE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causality assessment. A TEAE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. Any worsening (i.e., any clinical significant adverse change in frequency and/or intensity) of a preexisting condition, which was temporally associated with the use of the sponsor's medicinal (investigational) product, was also a TEAE. The number of participants with at least one TEAE are reported.

    Time frame: From first dose to termination visit on Day 169

  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug

    A treatment emergent adverse event (TEAE) related to study drug was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, that was determined to be related to the study drug. A TEAE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product. Any worsening (i.e., any clinical significant adverse change in frequency and/or intensity) of a preexisting condition, which was temporally associated with the use of the sponsor's medicinal (investigational) product, was also a TEAE. The number of participants with at least one TEAE are reported. Treatment emergent adverse events were assessed by the investigator as possibly, probably, or definitely related to the study drug.

    Time frame: From first dose to termination visit on Day 169

  3. Number of Participants With Serious Adverse Events (SAEs)

    A Serious Adverse Event (SAE) was defined as any untoward medical occurrence that at any dose (including overdose) that was fatal, was life threatening, required or prolonged inpatient hospitalization, resulted in permanent or significant disability/incapacity, or was a congenital anomaly/birth defect. The number of participants with at least one serious adverse event are reported.

    Time frame: From first dose up to termination visit on Day 169

  4. Change From Baseline in Hemoglobin

    Summary of the change from baseline in hemoglobin (g/dL) by the pre-specified timepoints. Baseline was defined as the last measurement prior to dosing. Data were summarized for all treated participants who had at least 1 postdosing measurement.

    Time frame: Day 1 (baseline), Day 8, Day 29, Day 36, Day 57, Day 85, Day 113, Day 169

  5. Number of Participants With Electrocardiogram Abnormalities

    The number of participants with at least one clinically significant postbaseline electrocardiogram abnormality. The abnormalities included left ventricular hypertrophy, atrial fibrillation, sinus bradycardia, sinus tachycardia, and myocardial ischemia. Data is reported as the cumulative number of participants with abnormalities over the scheduled collection timepoints.

    Time frame: Pre-dose, Day 1, Day 92, and Day 169

  6. Number of Participants With Hypertension or Increased Blood Pressure

    The number of participants who experienced hypertension or an increase in blood pressure from baseline up to Day 92. Abnormal blood pressure was defined as: * Systolic blood pressure ≤ 90 or ≥ 180 mmHg * Systolic blood pressure change (increase or decrease) ≥ 20 mmHg * Diastolic blood pressure ≤ 60 or ≥ 100 mmHg * Diastolic blood pressure change (increase or decrease) ≥ 15 mmHg

    Time frame: From baseline up to Day 92

Secondary outcomes

  1. Number of Participants With Skeletal-related Events (SRE)

    Skeletal-related events are defined as pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression, within 2 weeks of study enrollment. They are determined by skeletal surveys, including x-rays of the skull, entire spine, pelvis, ribs, humeri, and femora.

    Time frame: From first dose up to 2 weeks post first dose

  2. Percent Change From Baseline in Bone Pain Visual Analog Scale (VAS)

    The visual analog scale (VAS) is a pain rating scale. Scores are based on the percent change from baseline (Day 1) in self-reported measures of symptoms that are recorded with a single handwritten mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale-"no pain" on the left end (0 cm) of the scale and the "worst pain" on the right end of the scale (10 cm). Measurements from the starting point (left end) of the scale to the patients' marks are recorded in centimeters and are interpreted as their pain. The values can be used to track pain progression for a patient or to compare pain between patients with similar conditions. In addition to pain, the scale has also been used to evaluate mood, appetite, asthma, dyspepsia, and ambulation.

    Time frame: From baseline (Day 1) to Day 29, Day 57, Day 85, Day 113, Day 141, Day 169

07

Results

Posted Oct 3, 2024

Participant flow

Participant flow — Overall Study
MilestonePlacebo0.1 mg/kg ACE 0110.3 mg/kg ACE 0110.5 mg/kg ACE 011
Started6888
Completed6677
Not completed0211
Withdrew: Investigator's request0010
Withdrew: Withdrew consent0100
Withdrew: Adverse event0101

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

A treatment emergent adverse event (TEAE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, regardless of causality assessment. A TEAE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. Any worsening (i.e., any clinical significant adverse change in frequency and/or intensity) of a preexisting condition, which was temporally associated with the use of the sponsor's medicinal (investigational) product, was also a TEAE. The number of participants with at least one TEAE are reported.

Time frame:
From first dose to termination visit on Day 169
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPlacebo0.1 mg/kg ACE 0110.3 mg/kg ACE 0110.5 mg/kg ACE 011
Number of Participants With Treatment Emergent Adverse Events (TEAEs)4778
PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug

A treatment emergent adverse event (TEAE) related to study drug was defined as any untoward medical occurrence in a participant administered a pharmaceutical product, that was determined to be related to the study drug. A TEAE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product. Any worsening (i.e., any clinical significant adverse change in frequency and/or intensity) of a preexisting condition, which was temporally associated with the use of the sponsor's medicinal (investigational) product, was also a TEAE. The number of participants with at least one TEAE are reported. Treatment emergent adverse events were assessed by the investigator as possibly, probably, or definitely related to the study drug.

Time frame:
From first dose to termination visit on Day 169
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug
ParticipantsPlacebo0.1 mg/kg ACE 0110.3 mg/kg ACE 0110.5 mg/kg ACE 011
Number of Participants With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug0101
PrimaryNumber of Participants With Serious Adverse Events (SAEs)

A Serious Adverse Event (SAE) was defined as any untoward medical occurrence that at any dose (including overdose) that was fatal, was life threatening, required or prolonged inpatient hospitalization, resulted in permanent or significant disability/incapacity, or was a congenital anomaly/birth defect. The number of participants with at least one serious adverse event are reported.

Time frame:
From first dose up to termination visit on Day 169
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsPlacebo0.1 mg/kg ACE 0110.3 mg/kg ACE 0110.5 mg/kg ACE 011
Number of Participants With Serious Adverse Events (SAEs)0103
PrimaryChange From Baseline in Hemoglobin

Summary of the change from baseline in hemoglobin (g/dL) by the pre-specified timepoints. Baseline was defined as the last measurement prior to dosing. Data were summarized for all treated participants who had at least 1 postdosing measurement.

Time frame:
Day 1 (baseline), Day 8, Day 29, Day 36, Day 57, Day 85, Day 113, Day 169
Reported as:
Mean · g/dL
Change From Baseline in Hemoglobin
g/dLPlacebo0.1 mg/kg ACE 0110.3 mg/kg ACE 0110.5 mg/kg ACE 011
Day 80.47 ± 0.2880.89 ± 1.2540.83 ± 0.5990.80 ± 0.844
Day 290.50 ± 0.607-0.91 ± 1.8440.66 ± 0.4570.96 ± 1.648
Day 361.02 ± 0.6430.73 ± 1.8731.00 ± 0.7871.48 ± 1.167
Day 570.53 ± 0.6020.47 ± 1.6821.09 ± 1.0221.00 ± 1.22
Day 850.78 ± 0.9580.57 ± 0.9070.86 ± 1.3231.56 ± 0.704
Day 1130.33 ± 0.7890.53 ± 1.1410.96 ± 1.6200.97 ± 1.024
Day 169/Early Termination0.13 ± 1.1400.57 ± 1.5000.33 ± 1.7630.03 ± 2.392
PrimaryNumber of Participants With Electrocardiogram Abnormalities

The number of participants with at least one clinically significant postbaseline electrocardiogram abnormality. The abnormalities included left ventricular hypertrophy, atrial fibrillation, sinus bradycardia, sinus tachycardia, and myocardial ischemia. Data is reported as the cumulative number of participants with abnormalities over the scheduled collection timepoints.

Time frame:
Pre-dose, Day 1, Day 92, and Day 169
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram Abnormalities
ParticipantsPlacebo0.1 mg/kg ACE 0110.3 mg/kg ACE 0110.5 mg/kg ACE 011
Number of Participants With Electrocardiogram Abnormalities4222
PrimaryNumber of Participants With Hypertension or Increased Blood Pressure

The number of participants who experienced hypertension or an increase in blood pressure from baseline up to Day 92. Abnormal blood pressure was defined as: * Systolic blood pressure ≤ 90 or ≥ 180 mmHg * Systolic blood pressure change (increase or decrease) ≥ 20 mmHg * Diastolic blood pressure ≤ 60 or ≥ 100 mmHg * Diastolic blood pressure change (increase or decrease) ≥ 15 mmHg

Time frame:
From baseline up to Day 92
Reported as:
Count of participants · Participants
Number of Participants With Hypertension or Increased Blood Pressure
ParticipantsPlacebo0.1 mg/kg ACE 0110.3 mg/kg ACE 0110.5 mg/kg ACE 011
Number of Participants With Hypertension or Increased Blood Pressure0102
SecondaryNumber of Participants With Skeletal-related Events (SRE)

Skeletal-related events are defined as pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression, within 2 weeks of study enrollment. They are determined by skeletal surveys, including x-rays of the skull, entire spine, pelvis, ribs, humeri, and femora.

Time frame:
From first dose up to 2 weeks post first dose
Reported as:
Count of participants · Participants
Number of Participants With Skeletal-related Events (SRE)
ParticipantsPlacebo0.1 mg/kg ACE 0110.3 mg/kg ACE 0110.5 mg/kg ACE 011
Number of Participants With Skeletal-related Events (SRE)0122
SecondaryPercent Change From Baseline in Bone Pain Visual Analog Scale (VAS)

The visual analog scale (VAS) is a pain rating scale. Scores are based on the percent change from baseline (Day 1) in self-reported measures of symptoms that are recorded with a single handwritten mark placed at one point along the length of a 10-cm line that represents a continuum between the two ends of the scale-"no pain" on the left end (0 cm) of the scale and the "worst pain" on the right end of the scale (10 cm). Measurements from the starting point (left end) of the scale to the patients' marks are recorded in centimeters and are interpreted as their pain. The values can be used to track pain progression for a patient or to compare pain between patients with similar conditions. In addition to pain, the scale has also been used to evaluate mood, appetite, asthma, dyspepsia, and ambulation.

Time frame:
From baseline (Day 1) to Day 29, Day 57, Day 85, Day 113, Day 141, Day 169
Reported as:
Mean · Percent change
Percent Change From Baseline in Bone Pain Visual Analog Scale (VAS)
Percent changePlacebo0.1 mg/kg ACE 0110.3 mg/kg ACE 0110.5 mg/kg ACE 011
Day 29-6.0 ± 12.25-9.4 ± 22.60-5.8 ± 25.03-6.4 ± 23.87
Day 57-7.2 ± 6.77-8.0 ± 26.09-11.0 ± 33.87-11.6 ± 26.34
Day 85-4.5 ± 3.78-12.7 ± 23.08-10.5 ± 37.50-11.1 ± 28.79
Day 113-3.5 ± 4.46-13.7 ± 25.03-12.3 ± 38.04-11.4 ± 29.43
Day 1410.7 ± 13.05-13.7 ± 25.26-15.0 ± 37.33-12.1 ± 32.79
Day 169-3.0 ± 7.59-14.7 ± 24.59-15.0 ± 38.40-13.6 ± 30.36

Adverse events

Collected over Participants were assessed for all-cause mortality from their randomization to study completion, (up to approximately 10 months). SAEs and Other AEs were assessed from first dose to Day 169.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ACE 011 0.1 mg/kg1/8 (12.5%)1/8 (12.5%)7/8 (87.5%)
ACE 011 0.3 mg/kg0/8 (0%)0/8 (0%)7/8 (87.5%)
ACE 011 0.5 mg/kg0/8 (0%)3/8 (37.5%)8/8 (100%)
Placebo0/6 (0%)0/6 (0%)4/6 (66.7%)
Most frequent serious events
Most frequent serious events
EventACE 011 0.1 mg/kgACE 011 0.3 mg/kgACE 011 0.5 mg/kgPlacebo
Atrial fibrillationCardiac disorders0/80/81/80/6
Sudden deathGeneral disorders1/80/80/80/6
PneumoniaInfections and infestations0/80/81/80/6
Pain in extremityMusculoskeletal and connective tissue disorders0/80/81/80/6
Pathological fractureMusculoskeletal and connective tissue disorders0/80/81/80/6
Most frequent other events
Showing 10 of 40
Most frequent other events
EventACE 011 0.1 mg/kgACE 011 0.3 mg/kgACE 011 0.5 mg/kgPlacebo
NeutropeniaBlood and lymphatic system disorders4/86/86/84/6
LeukopeniaBlood and lymphatic system disorders3/81/81/80/6
AnaemiaBlood and lymphatic system disorders1/81/82/80/6
GranulocytopeniaBlood and lymphatic system disorders2/81/81/80/6
ThrombocytopeniaBlood and lymphatic system disorders1/80/82/80/6
EosinophiliaBlood and lymphatic system disorders0/80/80/81/6
Myocardial ischaemiaCardiac disorders0/80/80/81/6
Sinus bradycardiaCardiac disorders0/80/80/81/6
FatigueGeneral disorders0/80/80/81/6
BronchitisInfections and infestations0/81/81/81/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo0.1 mg/kg ACE 0110.3 mg/kg ACE 0110.5 mg/kg ACE 011Total
Mean62.0 ± 7.9260.5 ± 13.2863.6 ± 7.5057.8 ± 12.3060.9 ± 10.42
Sex: Female, Male
Sex: Female, Male(Participants)Placebo0.1 mg/kg ACE 0110.3 mg/kg ACE 0110.5 mg/kg ACE 011Total
Female425415
Male263415
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo0.1 mg/kg ACE 0110.3 mg/kg ACE 0110.5 mg/kg ACE 011Total
American Indian or Alaska Native00000
Asian01001
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White678829
More than one race00000
Unknown or Not Reported00000
08

Study locations

2 sites
  • Investigative Site
    Moscow, Russian Federation
  • Investigative Site
    Saint-Petersburg, Russian Federation
09

References and documents

Publications

  • Abdulkadyrov KM, Salogub GN, Khuazheva NK, Sherman ML, Laadem A, Barger R, Knight R, Srinivasan S, Terpos E. Sotatercept in patients with osteolytic lesions of multiple myeloma. Br J Haematol. 2014 Jun;165(6):814-23. doi: 10.1111/bjh.12835. Epub 2014 Mar 21. PubMed 24650009 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2008 to primary completion in Aug 2009, 11 months.

Results were first posted in Oct 2024, 15 years 2 months after primary completion. A results delay was requested in Sep 2012.

Of 93 industry-sponsored phase 2 interventional studies under Multiple Myeloma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 77. This study's 11 months is below that.

Counting every sponsor, half of 506 studies reached it within 57 months; a quarter within 35 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2008
First posted
Sep 4, 2008
StartActual
Sep 1, 2008
Primary completionActual
Aug 1, 2009
CompletionActual
Aug 1, 2009
Results delay requested
Sep 11, 2012
Results first posted
Oct 3, 2024
Last update
Oct 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00747123
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Sep 4, 2008
Start date
Sep 1, 2008
Primary completion
Aug 1, 2009
Completion
Aug 1, 2009
Results posted
Oct 3, 2024
Last update
Oct 3, 2024

Study contacts

Abderrahmane Laadem, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion